301. Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins
- Author
-
Annemarie Hekman, J. J. Sein, E.M. Rankin, Cornelis J. M. Melief, L. T. Vlasveld, and Jos H. Beijnen
- Subjects
Interleukin 2 ,Cancer Research ,Protein Denaturation ,Continuous infusion ,medicine.medical_treatment ,Biological Availability ,chemical and pharmacologic phenomena ,Pharmacology ,Sodium Chloride ,law.invention ,Clinical study ,law ,Albumins ,parasitic diseases ,Recombinant interleukin-2 ,medicine ,Saline ,Infusion Pumps ,business.industry ,hemic and immune systems ,Biological activity ,biological factors ,Recombinant Proteins ,Cytokine ,Glucose ,Oncology ,Solubility ,Immunology ,Recombinant DNA ,Interleukin-2 ,business ,medicine.drug - Abstract
In a previous clinical study using a continuous infusion schedule of recombinant interleukin-2 (rIL-2) we noted a nearly complete loss of activity of EuroCetus rIL-2 when dissolved in 10 ml saline and infused at a very low rate through a plastic infusion device. In the present study, we demonstrated that the loss resulted from a concentration-dependent precipitation of rIL-2 in saline and adherence of the protein to the tubing material. These phenomena were not noted for four other rIL-2 muteins tested [Glaxo, Hoffmann-LaRoche, Amgen (2 muteins)]. EuroCetus rIL-2 was found to be completely soluble in water and 5% glucose.
- Published
- 1993